Lv41
510 积分 2024-07-23 加入
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
2小时前
已完结
637 Clinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease
3个月前
已关闭
637 Clinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease
3个月前
已关闭
637 Clinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease
3个月前
已关闭
Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594]
3个月前
已完结
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease
3个月前
已完结
Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
3个月前
已完结
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease
3个月前
已完结
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies
3个月前
已完结
Predictive value of the combination of infliximab trough levels and C reactive protein in secondary loss of response to infliximab after induced remission
3个月前
已完结
皖公网安备34019202002308
